ADMA Biologics Inc (ADMA)
Pretax margin
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 125,714 | 73,356 | 39,172 | -3,050 | -28,240 | -22,827 | -40,292 | -47,686 | -65,905 | -70,322 | -73,135 | -78,275 | -71,647 | -74,406 | -73,610 | -74,883 | -75,748 | -66,901 | -61,422 | -54,456 |
| Revenue (ttm) | US$ in thousands | 426,454 | 382,809 | 330,245 | 283,177 | 258,216 | 234,293 | 208,108 | 181,890 | 154,079 | 130,481 | 110,072 | 93,998 | 80,944 | 68,517 | 58,112 | 48,069 | 42,220 | 40,301 | 37,248 | 36,021 |
| Pretax margin | 29.48% | 19.16% | 11.86% | -1.08% | -10.94% | -9.74% | -19.36% | -26.22% | -42.77% | -53.89% | -66.44% | -83.27% | -88.51% | -108.59% | -126.67% | -155.78% | -179.41% | -166.00% | -164.90% | -151.18% |
December 31, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $125,714K ÷ $426,454K
= 29.48%
ADMA Biologics Inc's pretax margin, as indicated in the financial data, experienced a negative trend from March 31, 2020, to December 31, 2022, with percentages ranging from -151.18% to -42.77%. During this period, the company incurred losses exceeding its pre-tax income. However, from March 31, 2023, to December 31, 2024, the pretax margin gradually improved, turning positive in the latter periods. Notably, there was a significant turnaround in performance, with the pretax margin shifting from a negative -1.08% on March 31, 2024, to 29.48% on December 31, 2024. This positive trend indicates that the company's profitability before tax has strengthened significantly, suggesting potentially improved operational efficiency and financial performance.
Peer comparison
Dec 31, 2024